Literature DB >> 21876776

Hypertension in the elderly: Are we all on the same wavelength?

Sadip Pant1, Pritam Neupane, Khatri Chhetri Ramesh, Murari Barakoti.   

Abstract

Hypertension is of frequent occurrence in the elderly population. Isolated systolic hypertension (ISH) accounts for the majority of cases of hypertension in the elderly. ISH is associated with a 2-4-fold increase in the risk of myocardial infarction, left ventricular hypertrophy, renal dysfunction, stroke, and cardiovascular mortality. There have been many studies to determine the optimal treatment for hypertension in the elderly. Why, when and how to treat hypertension in the elderly was the scope of the majority of these trials. Despite countless efforts many aspects remain obscure. While a number of novel drugs are being developed, the issue of whether all antihypertensive drugs bestow parallel benefits or whether some agents offer a therapeutic advantage beyond blood pressure control remains of crucial importance. Furthermore, the response of the elderly to different antihypertensive agents also differs from that of younger patients and may explain some of the disparities in outcomes of trials conducted in elderly patients with hypertension.

Entities:  

Keywords:  Antihypertensive agents; Hypertension; Left ventricular hypertrophy; Myocardial infarction

Year:  2011        PMID: 21876776      PMCID: PMC3163241          DOI: 10.4330/wjc.v3.i8.263

Source DB:  PubMed          Journal:  World J Cardiol


  35 in total

1.  Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease.

Authors:  J He; P K Whelton
Journal:  J Hypertens Suppl       Date:  1999-06

2.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

Review 3.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.

Authors:  F Turnbull; B Neal; T Ninomiya; C Algert; H Arima; F Barzi; C Bulpitt; J Chalmers; R Fagard; A Gleason; S Heritier; N Li; V Perkovic; M Woodward; S MacMahon
Journal:  BMJ       Date:  2008-05-14

4.  Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III.

Authors:  S S Franklin; M J Jacobs; N D Wong; G J L'Italien; P Lapuerta
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

5.  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; M J Schwartz
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

Review 8.  Hypertension in the elderly. Implications and generalizability of randomized trials.

Authors:  C D Mulrow; J A Cornell; C R Herrera; A Kadri; L Farnett; C Aguilar
Journal:  JAMA       Date:  1994-12-28       Impact factor: 56.272

Review 9.  National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group.

Authors: 
Journal:  Hypertension       Date:  1994-03       Impact factor: 10.190

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.